Investigating the Influence of Glycosylation on Protein Conformation and Dynamics - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Investigating the Influence of Glycosylation on Protein Conformation and Dynamics
The authors review and discuss the influence of glycans on the conformation of a representative IgG1 biopharmceutical using H/DX-MS as an analytical tool.


Pharmaceutical Technology
Volume 34, pp. s12-s17

Effect of deglycosylation on the conformation of an IgG1 antibody

Recombinant monoclonal antibodies (rmAb) are an important class of biopharmaceutical proteins. Antibodies are used to treat a wide array of medical conditions from autoimmune diseases to cancer to various other diseases (22). Today, more antibodies are in biopharmaceutical development pipelines and in clinical programs then are any other class of protein (23). The most common therapeutic rmAb is the immunoglobulin gamma 1 (IgG1). The IgG1 is made up of two identical subunits, a so–called homodimer. It is also a glycosylated protein with an apparent molecular weight approaching 150 kDa. An IgG1 is composed of two identical heavy chains and two identical light chains that are covalently connected by disulfide bonds. On each heavy chain (typically on residue Asn298), there is a single N–linked biantennary type oligosaccharide (6, 24). For IgG1 antibodies, glycosylation is a major source of heterogeneity, as most antibody expression systems (such as Chinese Hamster Ovary cells (25)) are incapable of producing an antibody containing a glycan with a uniform structural composition. Changes in IgG1 glycosylation (i.e., different levels of sialic acid, galactose, fucose, high mannose structures) have been shown to induce thermal destabilization, influence effector function, drug clearance, and may also provoke an immunogenic response (3, 26). Therefore, understanding the impact that glycans have on the conformation of an IgG1 (or any other glycosylated protein) is very important.


Figure 3: A summary of the H/DX-MS results (24, 27) obtained when comparing different IgG1 glycovariants. (Top) Representative structure of an IgG1 antibody [PDB: 1HZH] (36) and common glycans. (Bottom) The left-hand panel shows the structural changes observed by H/DX-MS when the oligosaccharides were removed from the IgG1, while the right-hand panel shows the structural changes observed by H/DX-MS when only galactose was removed from the IgG1 oligosaccharide.
Recently, H/DX–MS was used to study the effect of glycans on the conformation of an intact IgG1 (24–27). It was demonstrated that complete removal of the IgG1 glycan resulted in differences in deuterium incorporation throughout the IgG1 Fc region (see Figure 3). Some regions were shown to incorporate more deuterium as a result of glycan removal, while other regions incorporated less deuterium. These data correlated nicely with previous structural studies on deglycosylated IgG1–Fc (26, 28). Since IgG1 glycans were shown by X–ray crystallography to make several contacts with many residues within the IgG1 Fc region (29), it is not surprising that removing the glycan results in a change in the IgG1 Fc conformation. This change in conformation ultimately resulted in thermal instability of the IgG1 Fc (30) and complete loss of effector function (27), relative to the native IgG1. Because glycans are thought to anchor the IgG1 Fc in a stable conformation, which promotes favorable interactions with effector function proteins. This and other results (31) suggest that removal of the glycans weakens the structural rigidity of the IgG1 Fc. As a result, glycan removal leads to a significant change in the conformation of the IgG1 Fc. The change observed by H/DX clearly indicates that structural perturbation may extend well beyond the protein regions directly in contact with the oligosaccharide. This type of change is indicative of allosteric effects, where perturbations in one region influence conformation at a distance.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here